Eversense XL is the world’s first long-term CGM, with exceptional accuracy and a fully implantable sensor that lasts for up to 180 days. It can help you better manage your diabetes1 by providing real-time insight into your changing glucose levels, which you can discreetly check on your compatible mobile device. People using Eversense say it helps them feel more confident about controlling their diabetes,2 and we hope it does the same for you.
Eversense XL CGM System
Up to 180-Days of Sensor Life
Other CGM systems require a sensor removal and reinsertion every 2 weeks or more, while the Eversense XL Sensor lasts up to 180 days.
Smart Transmitter
Eversense XL offers you the flexibility and discretion to remove the transmitter without wasting a sensor.
iOS and Android App
With Eversense XL, you can see your readings directly on your compatible mobile device. And with readings every 5 minutes, you can see where you are now and where you’re headed with the trend arrows.3
Eversense XL CGM System
Eversense XL is the first and only long-term CGM that has a sensor that lasts up to 180 days and is changed by your health care provider - no more weekly self-insertions. Eversense provides you with the freedom you've always wanted in a CGM.
-
288 readings every 24 hours
Glucose readings and trend arrows every 5 minutes help show not only where you are, but where you're going, and can help you manage your diabetes before going too high or too low.Gentle, non-irritating adhesive
Eversense uses a gentle silicone-based adhesive that’s gentle on the skin.Alerts you can see, feel and hear
Eversense XL can send you pop-up messages on your phone, sound an alert or vibrate on your arm to alert you to highs and lows, based on your customized settings.No Sensor Self-Insertion
Eversense XL is inserted by your health care provider and lasts up to 180 days, letting you avoid the burdensome self-insertion process every 7-14 days.
1 Kropff, J., Choudhary, P., Neupane, S., Barnard, K., Bain, S. C., Kapitza, C., ... & DeVries, J. H. (2017). Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial. Diabetes Care, 40(1), 63-68.
2 Christiansen, M. P., Klaff, L. J., Brazg, R., Chang, A. R., Levy, C. J., Lam, D., ... & Kelley, L. (2018). A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. Diabetes Technology & Therapeutics. (PRECISE II).7. Glycemic Targets: Standards of Medical Care in Diabetes-2018 Diabetes Care 2018;41(Suppl. 1):S55–S64
3 Data on file.
